Viking Therapeutics (VKTX) CCO awarded 180,000 stock options at $31.76

Rhea-AI Filing Summary

Viking Therapeutics Chief Commercial Officer Neil William Aubuchon received a grant of stock options on common stock. The award covers 180,000 stock options with an exercise price of $31.76 per share, expiring on 01/12/2036.

According to the vesting terms, 25% of the options vest immediately, and an additional 25% vest on each one-year anniversary of the grant date over the next three years. After this grant, Aubuchon directly holds 180,000 derivative securities in the form of these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aubuchon Neil William

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	180,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 180,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aubuchon Neil William

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 350

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.76	01/12/2026		A		180,000		(1)	01/12/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. 25% of the shares subject to the option will vest immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years.

	/s/ Michael Morneau, as Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Viking Therapeutics (VKTX) report for its Chief Commercial Officer?

The filing shows Chief Commercial Officer Neil William Aubuchon received 180,000 stock options on Viking Therapeutics common stock.

What is the exercise price and expiration date of the new VKTX stock options?

The stock options have an exercise price of $31.76 per share and an expiration date of 01/12/2036.

How do the 180,000 Viking Therapeutics stock options vest?

25% of the options vest immediately, and 25% vest on each one-year anniversary of the grant date over the next three years.

How many derivative securities does Neil Aubuchon hold after this VKTX transaction?

Following the reported grant, Neil Aubuchon beneficially owns 180,000 derivative securities in the form of these stock options.

Is Neil Aubuchon’s ownership in Viking Therapeutics direct or indirect?

The Form 4 indicates that the 180,000 stock options are held with direct (D) ownership by Neil Aubuchon.

What role does Neil Aubuchon hold at Viking Therapeutics (VKTX)?

Neil William Aubuchon serves as Chief Commercial Officer of Viking Therapeutics.